Abstract
Analysis of selected genetic variants in psoriasis susceptibility and response to treatment
- Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland
- Aesthetic Dermatology Centre “Hippocrates”, Szczecin, Poland
- The 2nd Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland
Introduction
Aetiology of psoriasis is complex with risk factors involving both environmental triggers and genetic background. Although the best characterized genetic risk factor for psoriasis is HLA-C*06 allele, a number of other variants were associated with the disease.
Aim
In the current paper we have conducted a confirmation study for SNPs located in 9 gene regions in a case-control analysis of 507 psoriatic patients and 396 controls from the Polish population.
Material and methods
Subsequently the impact of genetic variants on response to topical and NB-UVB therapy (reduction in the Psoriasis Area and Severity Index) was analysed.
Results
Significant differences in genotype and/or allelic frequency were observed for the following SNPs: rs33980500 (TRAF3IP2), rs582757 (TNFAIP3I), rs12188300 (IL12B), rs28998802 (NOS2), and rs2233278 (TNIP1). None of the genetic factors was associated with treatment outcome.
Conclusions
Although the genetic variants have an impact on the disease risk, they are unlikely to be useful in personalization of topical therapy.
Keywords
psoriasis, SNP, NB-UVB
Indexed in
Integrated with
